Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma

NCT07082439 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Adenocarcinoma Metastatic in the Liver

Interventions

DRUG: Pembrolizumab
DRUG: Odetiglucan

Sponsor

Abramson Cancer Center at Penn Medicine

Collaborators

[object Object]